Par Pharmaceutical releases HCI injection in U.S.

The newly shipped HCI as an injection is the generic form of CellCept, which is a registered trademark of Hoffman-LaRoche Inc.
The newly shipped HCI as an injection is the generic form of CellCept, which is a registered trademark of Hoffman-LaRoche Inc. | File photo
Endo International plc subsidiary Par Pharmaceutical has released mycophenolate mofetil hydrochloride (HCI) as an injection in the United States after the Food and Drug Administration (FDA) gave its approval of Endo’s Abbreviated New Drug Application.
The newly shipped HCI as an injection is the generic form of CellCept, which is a registered trademark of Hoffman-LaRoche Inc. With its release, Par’s HCI as an injection is the first and the only generic injection on the market at this time. In a 12-month period that ended Oct. 31, CellCept’s sales in the U.S. were approximately $42 million. These numbers are according to data from IMS Health.
HCI as an injection will be sold in four 500 mg single dose vials per carton.